These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2889251)

  • 41. Influence of beta-blockade with beta-1-selectivity or intrinsic sympathomimetic activity on some metabolic responses to exercise.
    Yonga GO; Oyuga HW; Njeru EK
    East Afr Med J; 1993 Jul; 70(7):402-4. PubMed ID: 7904930
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pindolol: a comparison with other antihypertensive drugs and a double-blind placebo trial.
    Waal-Manning HJ; Simpson FO
    N Z Med J; 1974 Aug; 80(522):151-7. PubMed ID: 4608769
    [No Abstract]   [Full Text] [Related]  

  • 43. [Comparative effects of seven beta adrenolytic agents on blood pressure after injection into the posterior hypothalamus of rats. The frequency heart and the plasma renin activity (author's transl)].
    Bentue-Ferrer D; Allain H; Van den Driessche J; Pape D; Reymann JM
    J Pharmacol; 1981; 12(2):161-77. PubMed ID: 6115097
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Transdermal beta blockers: effect on 24-hour blood pressure profile in hypertensive patients].
    Spieker C; Vetter W; Hany S; Liedke R; Vetter H
    Schweiz Rundsch Med Prax; 1987 Apr; 76(17):467-8. PubMed ID: 3602765
    [No Abstract]   [Full Text] [Related]  

  • 45. [Single daily dose of pindolol in the treatment of arterial hypertension].
    Ciaramelli F
    Nouv Presse Med; 1978 Sep; 7(31):2761-4. PubMed ID: 30958
    [No Abstract]   [Full Text] [Related]  

  • 46. [Effects of nitroglycerin on exercise hemodynamics in patients with coronary heart disease under treatment with beta-blockers (mepindolol, oxprenolol) and a calcium-antagonist (fendiline) (author's transl)].
    Reiterer W
    Wien Med Wochenschr; 1980 Dec; 130(23):772-7. PubMed ID: 6111161
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect of beta-adrenergic blockade (Visken) on heart rate orthoclinostatic response and on hypertensive pressor reflex in a mental exertion model (author's transl)].
    Chrástek J; Kavánková M
    Sb Lek; 1976 May; 78(5):133-40. PubMed ID: 935792
    [No Abstract]   [Full Text] [Related]  

  • 48. [Beta blocking effects of butofilolol in standard exercise tests in the healthy subjects].
    Letac B; Bousnina A; Cribier A; Berland J
    Ann Cardiol Angeiol (Paris); 1982; 31(5):405-8. PubMed ID: 6130740
    [No Abstract]   [Full Text] [Related]  

  • 49. A preliminary report on the duration of beta-blockade after oral intake of L-B46.
    Bertil OS; Varnauskas E
    Indian Heart J; 1972 Jun; 24():Suppl 1:167-71. PubMed ID: 4147274
    [No Abstract]   [Full Text] [Related]  

  • 50. [Differential effect of long-term beta1-selective and nonselective beta-receptor blockade on carbohydrate metabolism. Ergometric investigations in hypertensive patients (author's transl)].
    Franz IW; Lohmann FW
    Klin Wochenschr; 1980 Oct; 58(20):1155-61. PubMed ID: 6109038
    [No Abstract]   [Full Text] [Related]  

  • 51. Evaluating mepindolol in a test model of examination anxiety in students.
    Krope P; Kohrs A; Ott H; Wagner W; Fichte K
    Pharmacopsychiatria; 1982 Mar; 15(2):41-7. PubMed ID: 6123122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet.
    Aellig WH; Narjes HH; Nüesch E; Oertle RJ; Devos JE; Pacha W
    Eur J Clin Pharmacol; 1981; 20(3):179-83. PubMed ID: 7286035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hemodynamic effects of strophanthin and pindolol in patients with hypertrophic cardiomyopathy.
    Storstein L; Abrahamsen AM; Storstein O
    Eur Heart J; 1981 Aug; 2(4):297-305. PubMed ID: 6117467
    [No Abstract]   [Full Text] [Related]  

  • 54. Local and systemic effects of pindolol eye drops.
    Mekki QA; Penhall R; Edgar DF; Stewart-Jones JH; Turner P
    Br J Clin Pharmacol; 1983 Jan; 15(1):112-3. PubMed ID: 6849733
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral pindolol in acute evolving myocardial infarction.
    O'Rourke MF; Baron D; Washington H; Sammel N; Le Cheminant D
    Aust N Z J Med; 1979 Aug; 9(4):408-11. PubMed ID: 41510
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ambulatory blood pressure during administration of atenolol, metoprolol, pindolol, and slow release propranolol.
    Br Med J (Clin Res Ed); 1983 Jan; 286(6361):306-7. PubMed ID: 6130815
    [No Abstract]   [Full Text] [Related]  

  • 57. Pharmacokinetics and pharmacodynamics of a new transdermal delivery system for bopindolol.
    Drewe J; Meier R; Timonen U; Thumshirn M; Munzer J; Kissel T; Gyr K
    Br J Clin Pharmacol; 1991 Jun; 31(6):671-6. PubMed ID: 1678271
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Copper(II) complexes of the beta-blocker pindolol: properties, structure, biological activity.
    Bontchev PR; Pantcheva IN; Bontchev RP; Ivanov DS; Danchev ND
    Biometals; 2002 Mar; 15(1):79-86. PubMed ID: 11860026
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiac dose-response relationships of oral and intravenous pindolol.
    Carruthers SG
    Br J Clin Pharmacol; 1982; 13(Suppl 2):193S-198S. PubMed ID: 7104142
    [No Abstract]   [Full Text] [Related]  

  • 60. Relationship between pharmacokinetic and pharmacodynamic behaviour of bufuralol and its metabolite Ro 3-7410 in hypertensive patients.
    Eckert M; Cocco G; Strozzi C; Heizmann P; Sfrisi C
    Eur J Clin Pharmacol; 1983; 24(4):479-84. PubMed ID: 6134625
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.